Subscribe To
GMED / Why Globus Medical Stock Is Sinking Today
GMED News
By Seeking Alpha
September 13, 2023
Globus Medical: Almost Having My Back
Globus Medical, Inc. shares have seen a significant pullback after announcing a $3 billion deal to acquire NuVasive. The company has a strong track re more_horizontal
By Zacks Investment Research
September 8, 2023
Globus Medical (GMED) Launches NuVasive's NSO in Global Market
Globus Medical's (GMED) Precice Bone Transport is a less intrusive treatment that reduces complications for both the patient and the surgeon and is de more_horizontal
By Zacks Investment Research
September 4, 2023
Globus Medical (GMED) Completes NuVasive Merger Agreement
Globus Medical's (GMED) recent deal combines complementary spine and orthopedic solutions, enabling technologies to create one of the industry's most more_horizontal
By Zacks Investment Research
August 4, 2023
Globus Medical (GMED) Q2 Earnings Beat Estimates, Margins Dip
According to Globus Medical (GMED), the increase in R&D expenses is largely focused on Spine and Enabling Technologies. more_horizontal
By Zacks Investment Research
August 3, 2023
Here's What Key Metrics Tell Us About Globus Medical (GMED) Q2 Earnings
The headline numbers for Globus Medical (GMED) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to more_horizontal
By Zacks Investment Research
July 31, 2023
Globus Medical (GMED) Gains on Innovation, Strategic Deal
Globus Medical's (GMED) Enabling technology sales improvement is driven by strong performance of its robotic and imaging system. more_horizontal
By Zacks Investment Research
July 26, 2023
ITGR or GMED: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Instruments sector might want to consider either Integer (ITGR) or Globus Medical (GMED). But which of t more_horizontal
By Seeking Alpha
July 18, 2023
Globus Medical: Robotics Demand Ratcheting Higher, Reiterate Buy
Globus Medical's Q1 sales grew by 21% YoY to a record $277m, driven by robust musculoskeletal sales and demand for its robotics offerings. The company more_horizontal